Key Takeaways BSX's Q2 revenues are estimated at $4.89B, up 18.7% Y/Y, with EPS expected to rise 16.1% to 72 cents. BSX's MedSurg may have seen gains from Axios, OverStitch and Axonics-driven Urology portfolio expansion. BSX's Cardiovascular unit may have benefited from imaging, embolization tech and vascular portfolio growth.Boston Scientific (BSX) is slated to report second-quarter 2025 results on July 23, before the market opens.The renowned medical device manufacturer posted earnings per share (EPS) o ...